Stiripentol

Chemical formula: C₁₄H₁₈O₃  Molecular mass: 234.295 g/mol  PubChem compound: 5311454

Therapeutic indications

Stiripentol is indicated for:

Severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome)

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Stiripentol is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet’s syndrome) whose seizures are not adequately controlled with clobazam and valproate.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Stiripentol is contraindicated in the following cases:

Past history of psychoses in the form of episodes of delirium

H/O: Disorder and additionally
Psychotic disorder and additionally Delirium

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: DIACOMIT Capsule / Powder for suspension
Summary of Product Characteristics (SPC) 2021: DIACOMIT Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈